Identification of Type 2 von Willebrand Disease in Previously Diagnosed Type 1 Patients: a Reappraisal Using Phenotypes, Genotypes and Molecular Modelling
- 1 January 2000
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (12) , 998-1004
- https://doi.org/10.1055/s-0037-1614162
Abstract
In order to investigate the possibility that qualitative type 2 defects in von Willebrand factor (VWF) occurred in patients previously diagnosed with quantitative type 1 von Willebrand disease (VWD), the phenotypes and genotypes were reanalysed in 30 patients who exhibited discrepant VWF activity/VWF:Ag ratios of less than 0.7. The capacity of VWF to bind to glycoprotein Ib (GpIb) was reassessed using the ristocetin co-factor activity (VWF:RiCo) assay compared to an in-house and a commercial ELISA assay (based on a mAb directed against the GpIb binding site on VWF). This was supplemented by multimeric analysis and the amplification and sequencing of a 936 bp fragment of exon 28 of the VWF gene with the aim of identifying mutations in the A1 domain. On reappraisal, using the VWF:RiCo assay all patients demonstrated a disproportionately reduced VWF:RiCo/VWF:Ag ratio, indicative of a qualitative defect, while abnormal ratios were detected in only seven kindreds using the in-house ELISA assay and in only one kindred with the commercial ELISA assay. Eight single amino acid substitutions were found in nine kindreds, four of which were novel candidate VWF mutations and four previously described in association with type 2 VWD. In agreement with the phenotype, the novel VWF mutations were located in the VWF-A1 crystal structure at positions that corresponded to potential type 2M defects. This study underlines the difficulties of correct diagnosis of the subtype of VWD and emphasises the importance of using sensitive phenotypic assays, the relevance of the VWF:RiCo/ VWF:Ag ratio, multimeric analysis and molecular modelling analysis.Keywords
This publication has 13 references indexed in Scilit:
- Mapping the Glycoprotein Ib-binding Site in the von Willebrand Factor A1 DomainJournal of Biological Chemistry, 2000
- Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin by Charged-to-Alanine Scanning MutagenesisJournal of Biological Chemistry, 2000
- Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding historyBritish Journal of Haematology, 2000
- Diagnosis of von Willebrand diseaseHaemophilia, 1998
- Crystal Structure of the von Willebrand Factor A1 Domain and Implications for the Binding of Platelet Glycoprotein IbJournal of Biological Chemistry, 1998
- Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 FabNature Structural & Molecular Biology, 1998
- Laboratory assays for von Willebrand Factor: relative contribution to the diagnosis of von Willebrand’s diseasePathology, 1997
- Effects of the mutant von Willebrand factor gene in von Willebrand diseaseHuman Genetics, 1995
- von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.Proceedings of the National Academy of Sciences, 1992
- The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.Journal of Clinical Investigation, 1991